NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win ® technology platform, ...
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback